Biotechnology News

Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a...

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader in RNA editing-based gene therapy, today announced that it has been awarded a research grant from The Michael J. Fox...

HOUSTON, July 29, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application and Fast Track...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 29, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...

Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 29. Juli 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,...

与一家大型制药公司达成长期商业合作，助力其在主要市场推进生产许可及商业化监管审批客户选择 AGC Biologics 横滨新基地，用于推进五项商业化生物制剂项目彰显市场对地缘政治稳定供应链的日益增长需求，同时推动日本成为全球生物制药供应体系中的战略枢纽 日本横滨, July 29, 2026 (GLOBE NEWSWIRE) -- 在 AGC Biologics...

與一家大型製藥公司達成長期商業合約，該公司目前正於主要市場尋求製造與商業監管許可客戶委託 AGC Biologics 位於橫濱的新生產基地負責五項商業生物製劑計劃突顯市場對地緣政治穩定供應鏈的需求日益增長，奠定日本作為全球生物製藥供應之盟國樞紐的地位 日本橫濱, July 29, 2026 (GLOBE NEWSWIRE) -- 在 AGC Biologics...

主要市場での製造および規制当局による商業承認を目指す大手製薬会社との長期商業契約顧客は、5つの商業用バイオ医薬品プログラムについて、AGCバイオロジクスの横浜新拠点での製造を決定地政学的に安定したサプライチェーンへの需要の高まりを浮き彫りにし、日本をバイオ医薬品のグローバル供給における提携拠点として位置づける 日本・横浜発, July 29, 2026 (GLOBE NEWSWIRE) --...

주요 시장에서 제조 및 상업화 규제 승인을 추진 중인 글로벌 대형 제약사와 장기 상업 생산 계약 체결고객사, 바이오의약품 상업화 프로그램 5건을 위해 AGC Biologics의 신규 요코하마 생산시설 이용 확정지정학적으로 안정적인 공급망에 대한 수요 증가를 반영하며, 일본을 글로벌 바이오의약품 공급의 핵심 거점으로 부각 일본 요코하마, July 29,...